

204020" FF20600F

Western Blot of Flk-1/SEAPS Immunoprecipitation with MAb DC101





Figure 1

Figure 2a



Probe: Anti-Ptyr

MAB (5µg/ml) + + + + +
 VEGF (ng/ml) 80 40 20 10 0
 - 200

Anti-pTyr





Figure 3

Inhibition of VEGF-Flk-1/fms activation by prebound MAb DC101




Probe: Anti-Ptyr

Assay conditions: P: MAb prebound 15'; VEGF 15'
 C: Competitive assay; MAb + VEGF 15'

Figure 4

Figure 5



FACS Analysis of Anti-flk-1 MAb Binding to flk-1/fms Transfected 3T3 Cells (C441)




Figure 6

Saturation Binding of MAb DC101 to the Flk-1/fms Receptor on the Transfected 3T3 Cell Line C441




Figure 7

Immunoprecipitation of phosphorylated flk-1/fms from VEGF stimulated flk-1/fms transfected 3T3 cells.

Antibody: 1 2 3 4

■ ■ - 200

Anti-pTyr

- Antibodies:**
- 1) Rat anti-flk-2 IgG_{2a} 2A13
 - 2) Rat anti-flk-1 IgG₁ DC101
 - 3) Rat anti-flk-2 IgG₁ 23H7
 - 4) Rabbit anti-fms polyclonal IM 133

Figure 8

S nsitivity of VEGF induced phosphorylation of the Flk-1/fms receptor to inhibition by MAb DC101




Figure 9

Effect of MAb DC101 on CSF-1 induced phosphorylation of the FMS receptor.






Figure 10

Specificity of MAb DC101 neutralization of the activated flk-1/fms receptor

Condition:	Competitive	Prebound
VEGF ng/ml:	- - - 20 40 40 40	40 40 40
MAb:	1 2 3 - - 1 2 3	1 2 3
(5µg/ml)		
	... 	
		- 200

Anti pTyr



Anti-FMS

- Rat MAbs: 1) Anti-flk-1 IgG, DC101
2) Anti-flk-2 IgG, 23H7
3) Anti-flk-2 IgG_{2a}, 2A13

Figure 11

204050 FT 20600T




Figure 12

Immunoprecipitation of phosphorylated receptor bands from VEGF stimulated HUVEC cells




Figure 13





Figure 14

Effect of MAb DC101 on VEGF Receptor Forms in the Tumor Cell Lines A431 and 8161




IP: MAb DC101

Probe: Anti-pTyr


Figure 15

Figure 16
204060 TT20500T

Treatment of Glioblastoma
Xenografts with Rat anti-flk-2 Mab



Treatment of Glioblastoma
Xenografts with Rat anti-Flk-1 Mab



Statistical Analysis:

Flk-1 slope = 16.09

Flk-2 slope = 37.39

p value for Flk-1 versus Flk-2 tumor size = 0.0001

Figure 17

